A citation-based method for searching scientific literature

Mariam M AlHilli, Zahraa Al-Hilli. J Minim Invasive Gynecol 2019
Times Cited: 6

List of co-cited articles
22 articles co-cited >1

Times Cited
  Times     Co-cited

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017

Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.
K Passaperuma, E Warner, P A Causer, K A Hill, S Messner, J W Wong, R A Jong, F C Wright, M J Yaffe, E A Ramsay,[...]. Br J Cancer 2012

Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Youlia M Kirova, Dominique Stoppa-Lyonnet, Alexia Savignoni, Brigitte Sigal-Zafrani, Nicolas Fabre, Alain Fourquet. Eur J Cancer 2005

Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.
Elizabeth Gilbert, Emily C Zabor, Michelle Stempel, Debra Mangino, Alexandra Heerdt, Melissa Pilewskie. Ann Surg Oncol 2017

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Theresa Wagner, Henry T Lynch, Judy E Garber, Mary B Daly, Claudine Isaacs, Olufunmilayo I Olopade, Susan L Neuhausen, Laura van 't Veer,[...]. J Clin Oncol 2005

Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
Katrina Armstrong, J Sanford Schwartz, Thomas Randall, Stephen C Rubin, Barbara Weber. J Clin Oncol 2004

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
Andrea Eisen, Jan Lubinski, Jacek Gronwald, Pal Moller, Henry T Lynch, Jan Klijn, Charmaine Kim-Sing, Susan L Neuhausen, Lucy Gilbert, Parviz Ghadirian,[...]. J Natl Cancer Inst 2008

Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
D Gareth R Evans, Sarah L Ingham, Andrew Baildam, Gary L Ross, Fiona Lalloo, Iain Buchan, Anthony Howell. Breast Cancer Res Treat 2013

Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.
Bernadette A M Heemskerk-Gerritsen, Matti A Rookus, Cora M Aalfs, Margreet G E M Ausems, Johanna M Collée, Liesbeth Jansen, C Marleen Kets, Kristien B M I Keymeulen, Linetta B Koppert, Hanne E J Meijers-Heijboer,[...]. Int J Cancer 2015

Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Peter D Beitsch, Pat W Whitworth, Kevin Hughes, Rakesh Patel, Barry Rosen, Gia Compagnoni, Paul Baron, Rache Simmons, Linda Ann Smith, Ian Grady,[...]. J Clin Oncol 2019

Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
Allison W Kurian, Yun Li, Ann S Hamilton, Kevin C Ward, Sarah T Hawley, Monica Morrow, M Chandler McLeod, Reshma Jagsi, Steven J Katz. J Clin Oncol 2017

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
Kelly Metcalfe, Shelley Gershman, Parviz Ghadirian, Henry T Lynch, Carrie Snyder, Nadine Tung, Charmaine Kim-Sing, Andrea Eisen, William D Foulkes, Barry Rosen,[...]. BMJ 2014

Surgery for BRCA, TP53 and PALB2: a literature review.
Chin-Vern Song, Soo-Hwang Teo, Nur Aishah Taib, Cheng-Har Yip. Ecancermedicalscience 2018

Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.
Eric R Manahan, Henry M Kuerer, Molly Sebastian, Kevin S Hughes, Judy C Boughey, David M Euhus, Susan K Boolbol, Walton A Taylor. Ann Surg Oncol 2019

A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Saundra S Buys, John F Sandbach, Amanda Gammon, Gayle Patel, John Kidd, Krystal L Brown, Lavania Sharma, Jennifer Saam, Johnathan Lancaster, Mary B Daly. Cancer 2017

False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.
Stephany Tandy-Connor, Jenna Guiltinan, Kate Krempely, Holly LaDuca, Patrick Reineke, Stephanie Gutierrez, Phillip Gray, Brigette Tippin Davis. Genet Med 2018

Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
Kandice K Ludwig, Joan Neuner, Annabelle Butler, Jennifer L Geurts, Amanda L Kong. Am J Surg 2016

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Joanne Kotsopoulos, Jacek Gronwald, Beth Y Karlan, Tomasz Huzarski, Nadine Tung, Pal Moller, Susan Armel, Henry T Lynch, Leigha Senter, Andrea Eisen,[...]. JAMA Oncol 2018

Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Sushmita Gordhandas, Barbara M Norquist, Kathryn P Pennington, Rachel L Yung, Mary B Laya, Elizabeth M Swisher. Gynecol Oncol 2019

Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery.
Irene T Ma, Richard J Gray, Nabil Wasif, Kristina A Butler, Jeffrey L Cornella, Javier F Magrina, Paul M Magtibay, William J Casey, Raman Mahabir, Alanna M Rebecca,[...]. Ann Surg Oncol 2017

Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Unal Egeli, Gulsah Cecener, Berrin Tunca, Ismet Tasdelen. Cancer Invest 2006

Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
Magdalena Koczkowska, Monika Zuk, Adam Gorczynski, Magdalena Ratajska, Marzena Lewandowska, Wojciech Biernat, Janusz Limon, Bartosz Wasag. Cancer Med 2016

Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.
Muhammad U Rashid, Noor Muhammad, Saima Faisal, Asim Amin, Ute Hamann. BMC Cancer 2013

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
Marc D Schwartz, Caryn Lerman, Barbara Brogan, Beth N Peshkin, Chanita Hughes Halbert, Tiffani DeMarco, William Lawrence, David Main, Clinton Finch, Colette Magnant,[...]. J Clin Oncol 2004

Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India.
Anurag Mehta, Smreti Vasudevan, Sanjeev Kumar Sharma, Dushyant Kumar, Manoj Panigrahi, Moushumi Suryavanshi, Garima Gupta. Cancer Manag Res 2018

Cancer risks among BRCA1 and BRCA2 mutation carriers.
E Levy-Lahad, E Friedman. Br J Cancer 2007

Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population.
Caglayan Geredeli, Nurgul Yasar, Abdullah Sakin. Int J Breast Cancer 2019

Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2017

Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.
Lilian Jara, Sebastian Morales, Tomas de Mayo, Patricio Gonzalez-Hormazabal, Valentina Carrasco, Raul Godoy. Biol Res 2017

Genetic analysis of BRCA1 function in a defined tumor cell line.
R Scully, S Ganesan, K Vlasakova, J Chen, M Socolovsky, D M Livingston. Mol Cell 1999

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray. Int J Cancer 2015

Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Muhammad U Rashid, Noor Muhammad, Saima Faisal, Asim Amin, Ute Hamann. Breast Cancer Res Treat 2014

Analysis of VUS reporting, variant reinterpretation and recontact policies in clinical genomic sequencing consent forms.
Danya F Vears, Emilia Niemiec, Heidi Carmen Howard, Pascal Borry. Eur J Hum Genet 2018

Prediction of pathogenic mutations in patients with early-onset breast cancer by family history.
Fiona Lalloo, Jennifer Varley, David Ellis, Anthony Moran, Lindsay O'Dair, Paul Pharoah, D Gareth R Evans. Lancet 2003

The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.
Eunyoung Kang, Moon-Woo Seong, Sue K Park, Jong Won Lee, Jihyoun Lee, Lee Su Kim, Jeong Eon Lee, Sung Yong Kim, Joon Jeong, Sang Ah Han,[...]. Breast Cancer Res Treat 2015

Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.
Jeffrey N Weitzel, Kathleen R Blazer, Deborah J MacDonald, Julie O Culver, Kenneth Offit. CA Cancer J Clin 2011

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008

Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients.
D Torres, J Lorenzo Bermejo, M U Rashid, I Briceño, F Gil, A Beltran, V Ariza, U Hamann. Sci Rep 2017

Pathological characteristics of BRCA-associated breast cancers in Hispanics.
Veronica I Lagos-Jaramillo, Michael F Press, Charité N Ricker, Louis Dubeau, Phuong L Mai, Jeffrey N Weitzel. Breast Cancer Res Treat 2011

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.
Heidrun Gevensleben, Verena Bossung, Alfons Meindl, Barbara Wappenschmidt, Nikolaus de Gregorio, Ana Osorio, Atocha Romero, Reinhard Buettner, Birgid Markiefka, Rita Katharina Schmutzler. Virchows Arch 2014

Analysis of several BRCA1 and BRCA2 mutations in a hospital-based series of unselected breast cancer cases.
T Burcoş, D Cimponeriu, D A Ion, S Spandole, P Apostol, M Toma, I Radu, I Popa, S Stanilescu, E Popa. Chirurgia (Bucur) 2013

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland.
P Wojcik, M Jasiowka, E Strycharz, M Sobol, D Hodorowicz-Zaniewska, P Skotnicki, T Byrski, P Blecharz, E Marczyk, I Cedrych,[...]. Hered Cancer Clin Pract 2016

Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population.
Iulian Gabriel Goidescu, Gabriela Caracostea, Dan Tudor Eniu, Florin Vasile Stamatian. Clujul Med 2018

On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations.
Nancy Hamel, Bing-Jian Feng, Lenka Foretova, Dominique Stoppa-Lyonnet, Steven A Narod, Evgeny Imyanitov, Olga Sinilnikova, Laima Tihomirova, Jan Lubinski, Jacek Gronwald,[...]. Eur J Hum Genet 2011

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kirsi M Kuusisto, Aleksandra Bebel, Mauno Vihinen, Johanna Schleutker, Satu-Leena Sallinen. Breast Cancer Res 2011

Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
Esra Manguoğlu, Sefik Güran, Deniz Yamaç, Taner Colak, Mehmet Simşek, Mehmet Baykara, Mustafa Akaydın, Güven Lüleci. Cancer Genet Cytogenet 2010

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.